Fentanyl is under clinical development by IX Biopharma and currently in Phase I for Cancer Pain. According to GlobalData, Phase I drugs for Cancer Pain does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Fentanyl LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fentanyl (Wafernyl) is under development for the treatment of breakthrough cancer pain. The therapeutic candidate is formulated as a wafer and is administered through sublingual route. The drug candidate acts by targeting mu opioid receptor. It is developed based on WaferiX drug delivery technology.
It was also under development for the treatment of acute pain, post-operative pain and traumatic pain.
IX Biopharma overview
iX Biopharma is a pharmaceutical and nutraceutical company. It discover, develops and commercializes novel therapies to treat diseases targeting central nervous system. The company’s products include Wafesil, a sublingual oral wafer containing sildenafil citrate and Silcap, an oral ingestion containing sildenafil citrate for the treatment of male erectile dysfunction. iX Biopharma provides pipeline products such as Wafermine, a sublingual ketamine oral wafer used to manage moderate to severe pain and pioid analgesia, Xativa, a sublingual wafer containing cannabidiol (CBD) against anxiety, movement disorder and chronic inflammation condition. BnoX, a sublingual buprenorphine oral wafer for pain management and Wafernyl, a sublingual fentanyl oral wafer used in breakthrough of cancer pain. iX Biopharma utilizes its proprietary formulation Waferix Sublingual to develop its products. The company conducts its research and development activities in Singapore and Australia. iX Biopharma is headquartered in Singapore.
For a complete picture of Fentanyl’s drug-specific PTSR and LoA scores, buy the report here.